Articles

  • 1 month ago | bizjournals.com | Greg Ryan |Hannah Green

    The lease is one of the most significant life sciences real estate transactions in Greater Boston since the industry slowdown led to a major fall-off in demand more than two years ago. Biogen Inc. plans to move its headquarters into a 16-story Kendall Square tower to be developed by MIT and BioMed Realty, which would consolidate the biotech giant's once-sprawling operations in the neighborhood.

  • Jan 3, 2025 | nbcboston.com | Greg Ryan

    Analogic Corp., the Peabody-based maker of medical and airport-security equipment, plans to move its headquarters and hundreds of jobs to Salem, New Hampshire. The company had been on the lookout for a new facility since it sold its Centennial Drive headquarters to real estate developer Tishman Speyer and a partner in May for $77 million.

  • Dec 20, 2024 | nbcboston.com | Greg Ryan

    Biogen Inc. is in advanced negotiations to consolidate its Kendall Square operations in MIT's upcoming Volpe redevelopment, several real estate sources told the Business Journal, a move that would carry major ramifications for the neighborhood and a sluggish regional lab market. The university's real estate arm is about to begin demolishing Kendall's Volpe transportation complex to make way for nearly 3 million square feet of mixed-use development, including four commercial buildings.

  • Nov 22, 2024 | nbcboston.com | Greg Ryan

    MassDevelopment has named Navjeet Bal, a former Massachusetts revenue commissioner, as its next chief executive. Bal will replace Dan Rivera, who resigned abruptly from the quasi-public real estate and economic development agency this spring. Since then, MassDevelopment has been led on an interim basis first by Dan O'Connell, a board member and the former CEO of the Massachusetts Competitive Partnership, and then by deputy director Marcos Marrero. More on this story from Boston Business Journal

  • Nov 21, 2024 | nbcboston.com | Greg Ryan

    A lab building in Burlington that traded for $103 million two years ago is back on the market, with expectations that it could sell at around a third of that price, if not lower. When the global insurance giant MetLife bought the 109,000-square-foot Burlington BioCenter in November 2022, it was fully leased to three life sciences companies, Ultivue, ProtaGene and CANbridge. The building had just recently been converted from offices to labs. More on this story from Boston Business Journal

Contact details

Socials & Sites

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.

Start Your 7-Day Free Trial →